Incyte president Cagnoni sells $297,779 in common stock

Pablo J. Cagnoni, President and Global Head of R&D at Incyte Corp (NASDAQ:INCY), sold shares of the company’s common stock totaling $297,779 on October 15, 2026.

Mr. Cagnoni disposed of 2,642 shares of Incyte common stock at a price of $112.71 per share. Concurrently, he acquired an equal number of shares, 2,642, through the exercise of employee stock options. These shares were acquired at prices ranging from $61.18 to $71.93, with the total value of these acquisitions amounting to $173,741.

Following these transactions, Mr. Cagnoni directly holds 183,200 shares of Incyte common stock. This total includes shares issuable pursuant to previously reported restricted stock units and earned performance stock units that have not yet vested.The insider transaction comes as Incyte shares trade at $113.25, with the stock currently undervalued according to InvestingPro’s Fair Value analysis. The biopharmaceutical company trades at a P/E ratio of 14.49, which InvestingPro data suggests is attractive relative to its near-term earnings growth potential. Investors can access 10 additional ProTips and comprehensive financial metrics for Incyte on the platform.

In other recent news, Incyte Corporation has seen several updates regarding its stock ratings and drug approvals. H.C. Wainwright reiterated a Buy rating and maintained a $152 price target on Incyte, following clinical data from Verastem’s KRAS G12D inhibitor program. The firm highlighted competitive opportunities for Incyte’s KRAS G12D-selective drug candidate, INCB161734. UBS also adjusted its price target for Incyte, increasing it from $113 to $127, while maintaining a Neutral rating, due to pipeline growth and expected data presentations at upcoming conferences.

Stifel raised its price target for Incyte to $157, up from $145, maintaining a Buy rating. This adjustment follows investor meetings with Incyte’s CEO and VP of Investor Relations, focusing on the company’s late-stage pipeline developments. Additionally, H.C. Wainwright increased its price target to $152, citing the FDA approval of Atebrioz (zilurgisertib) for treating fibrodysplasia ossificans progressiva. The drug is expected to be available in the U.S. in October. These developments reflect ongoing interest and analysis from investment firms concerning Incyte’s current and future prospects.